124020-27-5
124020-27-5
Chemical Structure
Levosulpiride-d3
Synonym(s): RV-12309-d3;S-(-)-Sulpiride-d3
- CAS No.: 124020-27-5
- Formula:C15H20D3N3O4S
- Molecular Weight:344.44
IUPAC Name: (S)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(methoxy-d3)-5-sulfamoylbenzamide
InChIKey: BGRJTUBHPOOWDU-XTRIYBSESA-N
SMILES: C(NC[C@H]1N(CC)CCC1)(=O)C2=C(OC([2H])([2H])[2H])C=CC(S(N)(=O)=O)=C2
Biological Activity: Levosulpiride-d3 is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Levosulpiride-d3 | 99.79% | Levosulpiride-d3 is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levosulpiride (Standard) | ≥98% | Levosulpiride (Standard) is the analytical standard of Levosulpiride. This product is intended for research and analytical applications. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levosulpiride | 99.78% | Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Triebel J, et al. From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis. Front Endocrinol (Lausanne). 2017;8:342. Published 2017 Dec 11. [Content Brief]
